These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23244419)

  • 1. C. elegans as a genetic model system to identify Parkinson's disease-associated therapeutic targets.
    Vistbakka J; VanDuyn N; Wong G; Nass R
    CNS Neurol Disord Drug Targets; 2012 Dec; 11(8):957-64. PubMed ID: 23244419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caenorhabditis elegans as a model system for Parkinson's disease.
    Schmidt E; Seifert M; Baumeister R
    Neurodegener Dis; 2007; 4(2-3):199-217. PubMed ID: 17596715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caenohabditis elegans in Parkinson's disease drug discovery: addressing an unmet medical need.
    Nass R; Merchant KM; Ryan T
    Mol Interv; 2008 Dec; 8(6):284-93. PubMed ID: 19144901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder.
    Calahorro F; Ruiz-Rubio M
    Invert Neurosci; 2011 Dec; 11(2):73-83. PubMed ID: 22068627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease.
    Harrington AJ; Hamamichi S; Caldwell GA; Caldwell KA
    Dev Dyn; 2010 May; 239(5):1282-95. PubMed ID: 20108318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling Parkinson's Disease in
    Ma L; Li X; Liu C; Yan W; Ma J; Petersen RB; Peng A; Huang K
    Curr Pharm Des; 2022; 28(37):3033-3048. PubMed ID: 36111767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights from Caenorhabditis elegans on the role of metals in neurodegenerative diseases.
    Martinez-Finley EJ; Avila DS; Chakraborty S; Aschner M
    Metallomics; 2011 Mar; 3(3):271-9. PubMed ID: 21210060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Holothuria scabra extracts exhibit anti-Parkinson potential in C. elegans: A model for anti-Parkinson testing.
    Chalorak P; Jattujan P; Nobsathian S; Poomtong T; Sobhon P; Meemon K
    Nutr Neurosci; 2018 Jul; 21(6):427-438. PubMed ID: 28276260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C. elegans as a model system to accelerate discovery for Parkinson disease.
    Martinez BA; Caldwell KA; Caldwell GA
    Curr Opin Genet Dev; 2017 Jun; 44():102-109. PubMed ID: 28242493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Parkinsonian effects of β-amyrin are regulated via LGG-1 involved autophagy pathway in Caenorhabditis elegans.
    Wei CC; Chang CH; Liao VH
    Phytomedicine; 2017 Dec; 36():118-125. PubMed ID: 29157804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondria: prospective targets for neuroprotection in Parkinson's disease.
    Yadav A; Agarwal S; Tiwari SK; Chaturvedi RK
    Curr Pharm Des; 2014; 20(35):5558-73. PubMed ID: 24606805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of molecular mechanism of anti-Parkinson's disease traditional Chinese medicine using model of Caenorhabditis elegans].
    Wang X; Wang X; Gao H; Wang D
    Zhongguo Zhong Yao Za Zhi; 2010 Mar; 35(5):661-3. PubMed ID: 20506834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson's disease.
    Jadiya P; Khan A; Sammi SR; Kaur S; Mir SS; Nazir A
    Biochem Biophys Res Commun; 2011 Oct; 413(4):605-10. PubMed ID: 21925152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Traversing a wormhole to combat Parkinson's disease.
    Caldwell GA; Caldwell KA
    Dis Model Mech; 2008; 1(1):32-6. PubMed ID: 19048050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balancing Apoptosis and Autophagy for Parkinson's Disease Therapy: Targeting BCL-2.
    Liu J; Liu W; Yang H
    ACS Chem Neurosci; 2019 Feb; 10(2):792-802. PubMed ID: 30400738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective Effects of Betulin in Pharmacological and Transgenic Caenorhabditis elegans Models of Parkinson's Disease.
    Tsai CW; Tsai RT; Liu SP; Chen CS; Tsai MC; Chien SH; Hung HS; Lin SZ; Shyu WC; Fu RH
    Cell Transplant; 2017 Dec; 26(12):1903-1918. PubMed ID: 29390878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caenorhabditis elegans RAC1/ced-10 mutants as a new animal model to study very early stages of Parkinson's disease.
    Muñoz-Juan A; Benseny-Cases N; Guha S; Barba I; Caldwell KA; Caldwell GA; Agulló L; Yuste VJ; Laromaine A; Dalfó E
    Prog Neurobiol; 2024 Mar; 234():102572. PubMed ID: 38253120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of the Mitochondrial Unfolded Protein Response Induces Non-Apoptotic Dopaminergic Neurodegeneration in
    Martinez BA; Petersen DA; Gaeta AL; Stanley SP; Caldwell GA; Caldwell KA
    J Neurosci; 2017 Nov; 37(46):11085-11100. PubMed ID: 29030433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Parkinson activity of bioactive substances extracted from Holothuria leucospilota.
    Malaiwong N; Chalorak P; Jattujan P; Manohong P; Niamnont N; Suphamungmee W; Sobhon P; Meemon K
    Biomed Pharmacother; 2019 Jan; 109():1967-1977. PubMed ID: 30551452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubiquitin-proteasome system and Parkinson's diseases.
    Betarbet R; Sherer TB; Greenamyre JT
    Exp Neurol; 2005 Feb; 191 Suppl 1():S17-27. PubMed ID: 15629758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.